Invivyd, Inc. Share Price & Technical Analysis
IVVD · $1.10 (-0.90%)
Healthcare / Biotechnology
$1.10
-0.90%
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through inj…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-21% return in May, 27% avg return in past 3 year May month.
-78% return in 2026, 116% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -32% | -6% | -19% | 0% | -21% | – | – | – | – | – | – | – | -78% |
| 25 | -20% | 200% | -50% | 0% | 50% | -22% | 0% | 43% | 10% | 64% | 33% | 0% | 308% |
| 24 | 23% | -20% | 13% | -53% | -18% | -42% | 9% | -25% | 11% | -10% | -22% | -43% | -178% |
| 23 | 53% | -23% | -29% | -8% | 50% | -44% | 50% | 27% | -6% | -6% | -6% | 160% | 217% |
| 22 | 0% | -7% | -28% | -36% | 7% | 10% | 6% | 28% | -33% | 25% | -42% | -35% | -105% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$417.14M
P/E ratio
—
52W high
$3.07
52W low
$0.48
Volume
17,82,038
Beta
0.71
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Invivyd, Inc. share price today?
- Invivyd, Inc. (IVVD) last traded around $1.10 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IVVD have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IVVD. Download the app for real-time alerts.
- How can I analyze Invivyd, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.